Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Boehringer Ingelheim Pharma GmbH und Co. KG
This publication has 27 references indexed in Scilit:
- Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary FibrosisClinical Therapeutics, 2023
- Relative Versus Absolute Decline in Forced Vital Capacity in Progressive Pulmonary FibrosisArchivos de Bronconeumología, 2022
- Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesRespirology, 2022
- Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2021
- Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialThe Lancet Respiratory Medicine, 2021
- Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research prioritiesThe Lancet Respiratory Medicine, 2020
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Respiratory Medicine, 2020
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosisThe Clinical Respiratory Journal, 2017
- Analysis of Longitudinal Data in the Presence of Informative Observational Times and a Dependent Terminal Event, with Application to Medical Cost DataBiometrics, 2007